Q3 2025 Immunovia AB (publ) Earnings Call Transcript

Nov 26, 2025 / 02:00 PM GMT

Release Date Price: $0.05207

Transcript

Key Points

Positve

Immunovia AB (FRA:1YR) successfully transitioned from a development stage to a commercial stage company with the launch of the Pancreassure test.
The Pancreassure test has received positive feedback for its high sensitivity and specificity, making it a valuable option for high-risk patients.
The company has achieved significant reimbursement milestones, including receiving a billing code and a favorable Medicare reimbursement rate of $897.
Immunovia AB (FRA:1YR) has engaged key opinion leaders and leading pancreatic cancer centers, with 10 centers implementing the Pancreassure test within the first month of launch.
The company has a strategic plan for a phased launch, focusing on targeted advocacy, volume building, and revenue growth over the next few years.

Negative

The company has not yet secured coverage from Medicare or commercial insurers, which is crucial for widespread adoption and reimbursement.
Revenue generation from the Pancreassure test is expected to be delayed, with significant revenue not anticipated until 2026.
The company is operating with a limited sales force, relying on management for sales efforts, which may hinder rapid market penetration.
Immunovia AB (FRA:1YR) is still in the early stages of building clinical utility evidence, which is necessary for securing insurance coverage.
The company's cash position, while bolstered by a rights issue, is limited, and it anticipates increased cash burn as it ramps up commercial activities.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMMNOV.ST - Immunovia AB (publ)
Q3 2025 Immunovia AB (publ) Earnings Call
Nov 26, 2025 / 02:00PM GMT

=====================
Conference Call Participants
=====================
* Herman Kuntscher
Carlsquare AB - Equity Analyst

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified Company Representative, [1]
--------------------------------------------------------------------------------
Good afternoon, good morning, and welcome to the Q3 interim report for Iunovia. I'm excited to speak with you today about the milestones we've achieved. And the progress that we've made in our mission to save lives through early detection of pancreatic cancer. This is a really important quarter for us as it marked the transition from being a development stage company to being a commercial stage company where we brought our Pancreassure test to the market and saw the initial response to that.

We have been very excited about the responses that we've

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.